PT  - JOURNAL ARTICLE
AU  - Aderike Anjorin
AU  - Peter Lipsky
TI  - Engaging African ancestry participants in SLE clinical trials
AID  - 10.1136/lupus-2018-000297
DP  - 2018 Dec 01
TA  - Lupus Science & Medicine
PG  - e000297
VI  - 5
IP  - 1
4099  - http://lupus.bmj.com/content/5/1/e000297.short
4100  - http://lupus.bmj.com/content/5/1/e000297.full
AB  - SLE is a complex autoimmune disease with genetic and clinical differences between patients that appear to reside along ancestral lines. Over the last 20 years, a preponderance of evidence has shown that SLE is more common and severe in minority populations, particularly in African ancestry (AA) women. However, in clinical trials for new therapies of SLE, AA is often under-represented. Without enrolling sufficient AA participants, it is difficult to ascertain the safety and efficacy of new potential therapies among individuals with SLE of different ancestries. Although enrolling minority populations in clinical trials has been a significant challenge for many reasons, the various stakeholders involved in clinical research could act within their own realms to develop new paradigms and policies to bolster the inclusion of AA in the development of new therapies.